2 Biotech Stocks Deutsche Bank Just Initiated – Sagent … – Benzinga

2 Biotech Stocks Deutsche Bank Just Initiated – Sagent … – Benzinga


SGNT5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 YearsPorat To Google Just One Of The Week’s Top Management Changes; Here Are 7 More


IPXLFTC Requires Divestitures in Connection With Impax Laboratories Inc.’s Proposed Acquisition of CorePharma, LLCJPM Securities Picks Through Biotech News For WinnersMylan makes $205/share bid for Perrigo; Generic firms rally(Seeking Alpha)

Shares of Sagent Pharmaceuticals Inc (NASDAQ: SGNT) and Impax Laboratories Inc (NASDAQ: IPXL) were up on Wednesday, after analysts at Deutsche Bank initiated coverage on Tuesday.

Sagent Pharmaceuticals

The analysts initiated coverage of Sagent with a Buy rating and a $29 price target. They say they have always liked the biotech company’s “focus on the attractive generic injectables segment but now believe the recent weakness in the shares creates a favorable risk/reward.”
While the firm sees the sudden departure of CEO and Founder Jeff Yordon as a source of uncertainty, they believe “the operating team can manage the business, deliver on its targets, and create value over time.”

In the meantime during the management transition, the analysts would not be surprised to see the Board pursue options in light of the company’s underperformance when compared to its peers in recent years, stock ownership concentration and the scarcity value of injectable assets.

Impax Laboratories

Impax was initiated at Hold with a $50 price target. The analysts said the biotech company has made “significant progress with addressing its manufacturing issues, which have been an overhang for the stock since 2011 and could be resolved this year.”

Deutsche Bank likes Impax’s recent acquisitions, which contributed to the diversification of the revenue base, added two products with considerable growth potential to the portfolio, expanded the generics pipeline, and strengthened the manufacturing base.

Having said that, the stock’s year-to-date appreciation, which surpasses 50 percent, has probably priced in the success. The analysts think that “significant upside from here could require stronger uptake for Rytary, greater new generic flow (some of which may be tied to resolution of the Hayward issues), and business development activity (which was predicted by management).”

Latest Ratings for SGNT

Apr 2015
Deutsche Bank
Initiates Coverage on

Dec 2014

Oct 2014


View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Biotech Health Care Price Target Initiation Analyst Ratings General

Follow this link – 

2 Biotech Stocks Deutsche Bank Just Initiated – Sagent … – Benzinga

Share this post